JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

JAK2 mutation status, hemostatic risk factors and thrombophilic factors in essential thrombocythemia (ET) patients

The recently discovered JAK2 V617F point mutation, found in 50–60% of ET patients, has been reported to be associated with a higher risk of thrombotic events. In this study, we explored if JAK2 V617F mutation, or coexisting thrombophilic and hemostatic risk factors, contributed to thes...

Description complète

Détails bibliographiques
Auteurs principaux: Anna Dmoszyńska, Martyna Kandefer-Szerszeń, Anna M. Kowalska, Tomasz Gromek, Adam Walter-Croneck, Katarzyna Wejksza, Sylwia Chocholska, Ksenia Bykowska, Aleksandra Nowaczyńska, Bożena Sokołowska
Format: Article
Langue:English
Publié: Via Medica 2011-07-01
Collection:Folia Histochemica et Cytobiologica
Sujets:
JAK2 mutation
ET
thrombophilic factors
Accès en ligne:http://czasopisma.viamedica.pl/fhc/article/view/4123

Internet

http://czasopisma.viamedica.pl/fhc/article/view/4123

Documents similaires